Freedom Capital cuts iRhythm Technologies stock price target on valuation By Investing.com
Freedom Capital has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) shares from $200 to $190, while maintaining a Buy rating. This adjustment comes despite iRhythm exceeding second-quarter revenue and EBITDA expectations, with strong growth and improved profitability. The firm cited valuation as the reason for the target cut, noting the stock appears overvalued relative to its Fair Value estimate.
Citizens Financial Group Inc. RI Buys New Shares in iRhythm Technologies $IRTC
Citizens Financial Group Inc. RI has acquired a new stake of 48,960 shares in iRhythm Technologies, valued at approximately $9.29 million, representing about 0.15% of the company. Despite recent target-price reductions, analysts maintain a "Moderate Buy" consensus with an average price target of $179.93 for IRTC. iRhythm Technologies also reported strong quarterly results, with revenue up 20.1% year over year and earnings per share beating analyst expectations.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of iRhythm stock to contact them to discuss their legal rights and options, including seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance transparency, accountability, and overall shareholder value.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
Analysts from Bank of America Securities and Jefferies have issued bullish sentiments on several healthcare companies. 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO), and Irhythm Technologies (IRTC) all received Buy ratings, with analysts citing significant upside potential from current levels. The article highlights specific analyst ratings, price targets, and the consensus among analysts for each company.
Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Citi has reiterated a Buy rating for Irhythm Technologies (IRTC) with a price target of $157.00. This comes despite a GAAP net loss for the company in its latest quarter, though revenue increased. Analyst consensus on the stock remains a Strong Buy, but insider sentiment is negative due to recent share sales.
iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in iRhythm Technologies by 41.7% in Q1, selling over 309,000 shares but still holding shares worth $51 million. Despite this reduction, iRhythm reported strong Q1 results with revenue up 20.1% year-over-year and earnings exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $179.93.
iRhythm Technologies (NASDAQ:IRTC) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given iRhythm Technologies (NASDAQ:IRTC) an average recommendation of "Moderate Buy," with a consensus price target of $179.93. The company recently reported strong quarterly earnings, beating expectations with an EPS of $0.58 and revenue of $224.17 million, a 20.1% year-over-year increase. Institutional investors, including Royal Bank of Canada and Goldman Sachs, have also increased their holdings in IRTC.
iRhythm Technologies $IRTC Shares Acquired by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 1,172.8% in the first quarter, now owning 18,621 shares valued at approximately $2.2 million. The company reported strong financial results, with quarterly revenue up 20.1% year over year to $224.17 million and EPS of $0.58, greatly surpassing analyst estimates. Despite some target price adjustments by analysts, iRhythm Technologies maintains a "Moderate Buy" consensus rating with an average price target of $179.93.
The Technical Signals Behind (IRTC) That Institutions Follow
This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), detailing institutional trading strategies based on AI models. It identifies strong near- and mid-term sentiment but a weak long-term outlook, with key support and resistance levels. The analysis also highlights a significant risk-reward short setup for the stock.
iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Truist Financial Analyst Says
Truist Financial has increased its price target for iRhythm Technologies (NASDAQ:IRTC) from $160 to $168, maintaining a "buy" rating and indicating a potential upside of 34.59%. This positive outlook aligns with a "Moderate Buy" consensus rating from MarketBeat analysts, despite some recent target reductions by other firms. The company recently surpassed earnings estimates, reporting $0.58 per share and a 20.1% year-over-year revenue increase to $224.17 million.
IRhythm to Gain From VitalConnect Deal, Rising Margins, Oppenheimer Says
Oppenheimer expects iRhythm Technologies to benefit from its acquisition of VitalConnect, which will add a significant product to its portfolio and is expected to be immediately accretive to margins. The firm reiterates an Outperform rating and a $170 price target for iRhythm, citing potential for margin expansion through better supply chain management and manufacturing. The analysis suggests that while VitalConnect is a smaller player, its technology complements iRhythm's offerings and enhances the company's competitive position.
Why iRhythm (IRTC) Shares Are Trading Lower Today
Shares of iRhythm Technologies (IRTC) fell after an analyst significantly cut their price target on the stock, despite the company reporting strong quarterly earnings and raising its full-year revenue guidance. Truist lowered its price target to $18 from $160, even while maintaining a "Buy" rating, which caused investor concern. The stock initially dropped but recovered some losses, with analysts suggesting such moves can present buying opportunities for high-quality stocks.
IRhythm grows heart monitoring leadership with $288M VitalConnect buy
IRhythm announced its acquisition of VitalConnect for $287.5 million to expand its mobile cardiac telemetry (MCT) capabilities. This acquisition is expected to unlock access to an additional $500 million market opportunity within the $1 billion cardiac monitoring market. While IRhythm remains committed to securing FDA clearance for its Zio MCT device, the immediate focus will be on integrating VitalPatch into its commercial operations by year-end.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (IRTC) for potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company misrepresented the Zio AT monitor's capabilities and market penetration, leading to artificially inflated stock prices. The law firm is encouraging long-term IRTC shareholders to contact them to discuss their rights.
Irhythm Technologies Boosts Outlook, Expands Cardiac Monitoring Platform
iRhythm Technologies (IRTC) recently settled a patent dispute for $50 million and announced strong Q2 2026 results, including a 20.1% revenue increase and improved margins. The company also secured FDA clearance for a new algorithm and plans to acquire Vital Connect for $287.5 million to expand its cardiac monitoring platform. Despite these positive developments, TipRanks' AI analyst, Spark, rates IRTC as "Neutral" due to balance sheet leverage and a bearish technical trend, noting that valuation support is limited by negative earnings and mixed corporate events.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) for potential breaches of fiduciary duties by its officers and directors. A federal lawsuit alleges that iRhythm insiders misrepresented or failed to disclose that the Zio AT monitor was intended for high-risk patients, leading to artificially inflated stock prices. The firm encourages long-term IRTC shareholders to contact them to enforce their rights, emphasizing that it covers all case costs.
iRhythm Technologies (NASDAQ:IRTC) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) to a "Hold" rating from "Buy," despite the company's strong Q2 results and a broader analyst consensus of "Moderate Buy." iRhythm reported earnings of $0.58 per share against an expected loss and saw revenue increase by 20.1% year-over-year. The company also announced the acquisition of VitalConnect for $287.5 million, expanding its cardiac-monitoring portfolio, and provided a positive 2026 revenue outlook.
iRhythm Technologies, Inc. Q2 2026 Earnings Call Summary
iRhythm Technologies reported its seventh consecutive quarter of over 20% revenue growth, driven by strong demand across cardiology, primary care, and international markets. The company announced the acquisition of VitalConnect to expand into new cardiac monitoring modalities and raised its full-year 2026 revenue guidance to $880 million-$890 million. Additionally, iRhythm resolved litigation with Baxter/Welch Allyn for a $50 million settlement and achieved FDA clearance for a new algorithm expected to significantly reduce review time and generate cost savings.
iRhythm advances cardiac monitoring provision with $287.5m VitalConnect acquisition
iRhythm has announced the acquisition of VitalConnect for $287.5 million, a move aimed at expanding its cardiac monitoring platform across various healthcare settings. The deal, expected to close by the end of 2026, combines cash and iRhythm common stock. This acquisition is anticipated to boost iRhythm's Zio platform by integrating VitalConnect's monitoring tools and expanding its market reach, complementing its strong Q2 financial performance with a 20.1% year-over-year revenue increase.
Needham cuts iRhythm Technologies stock price target on lower multiple By Investing.com
Needham has lowered its price target for iRhythm Technologies (NASDAQ: IRTC) to $192.00 from $255.00, while maintaining a Buy rating. This adjustment comes despite iRhythm exceeding second-quarter revenue expectations and raising its 2026 revenue guidance, as well as announcing the acquisition of VitalConnect which is expected to be accretive to growth and expand its market reach. The firm cited a lower target multiple as the reason for the reduced price target, noting that InvestingPro analysis suggests the stock may be overvalued despite its recent performance.
iRhythm Technologies Inc (IRTC) Stock News Today
This article provides current stock information for iRhythm Technologies Inc (IRTC), including its stock price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the TradingKey platform for investors.
Truist Securities Adjusts IRhythm Technologies PT to $168 From $160, Maintains Buy Rating
Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.
Needham cuts iRhythm Technologies stock price target on lower multiple
Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $192 from $255, while maintaining a Buy rating. The adjustment comes despite iRhythm exceeding Q2 2026 revenue expectations and raising its full-year guidance, partly due to the acquisition of VitalConnect which is expected to boost growth and maintain strong gross margins. Analysts anticipate profitability for iRhythm this year, although the firm's price target was reduced based on a lower target multiple.
IRTC Looks 22.6% Undervalued on GF Value™
iRhythm Technologies, Inc. (IRTC) reported strong Q2 revenue growth of 20.1% year-over-year, leading to raised full-year guidance and a strategic acquisition to expand its cardiac monitoring capabilities. Despite being unprofitable, the company is considered 22.6% undervalued based on its GF Value™ and shows strong fundamentals with a GF Score™ of 79, driven by high growth and valuation ranks. However, mixed guru ownership and net insider selling indicate cautious optimism and suggest that IRTC remains a speculative growth stock.
Earnings call transcript: iRhythm tops revenue view in Q2 2026 and stock rises
iRhythm Technologies (IRTC) reported strong Q2 2026 results, exceeding revenue forecasts and demonstrating significant margin expansion, leading to a stock increase. The company announced the acquisition of VitalConnect, which is expected to expand its cardiac monitoring offerings and accelerate its entry into new markets like inpatient monitoring and hospital-to-home care. iRhythm also raised its full-year 2026 revenue and adjusted EBITDA margin guidance, emphasizing continued focus on profitable growth, innovation, and strategic market expansion.
(IRTC) IRhythm Technologies Expects 2026 Revenue Range $880M - $890M, vs. FactSet Est of $881.1M
iRhythm Technologies (IRTC) has announced its revenue expectations for 2026, forecasting a range of $880 million to $890 million. This projection is in line with FactSet's estimated revenue of $881.1 million for the same period. The company also reported its Q2 2026 earnings, with revenue rising to $224.2 million, surpassing FactSet's estimate of $219.3 million, and adjusted EPS of $0.58, compared to an estimated $0.00.
iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across ambulatory, inpatient, and hospital-to-home care settings. The transaction is projected to enhance iRhythm's revenue growth rate starting in 2027 while maintaining its adjusted EBITDA margin target for the same year.
iRhythm earnings up next: Narrowing losses in focus tonight
iRhythm Technologies Inc. is scheduled to report second-quarter earnings, with analysts expecting a narrower loss of 5 cents per share and revenue of $219.3 million, indicating substantial improvement from the previous quarter. Investors will be focused on the company's ability to maintain rapid growth while accelerating its path to profitability, especially after raising full-year revenue and adjusted EBITDA margin guidance. Despite a significant stock price retreat from its 52-week high, all 15 analysts rate the stock a Buy, with a mean price target suggesting a 42% upside.
Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stock
Bernstein Litowitz Berger & Grossmann LLP announced a proposed class action settlement for purchasers of iRhythm Technologies, Inc. common stock. The $45,000,000 cash settlement aims to resolve claims alleging materially false and misleading statements regarding iRhythm's Zio AT heart monitoring device between July 25, 2022, and August 9, 2024. A settlement hearing is scheduled for November 5, 2026, to determine final approval and other related matters.
iRhythm Technologies $45M Securities Class Action Settlement
iRhythm Technologies and its CEO have agreed to a $45 million securities class action settlement. Investors who purchased the company's common stock between July 25, 2022, and August 9, 2024, may be eligible to claim a cash payment. The lawsuit alleged false and misleading statements were made about the Zio AT heart monitoring device, leading to inflated stock prices and investor losses.
iRhythm Technologies Inc (IRTC) Institutional Confidence
The article provides an analysis of iRhythm Technologies Inc's (IRTC) institutional confidence, noting its current score of 10.00, which ranks 1st in its industry. It details that the institutional shareholding proportion is 107.08%, with a slight decrease quarter-over-quarter. The largest institutional shareholder is Steven Cohen, and the article lists other significant institutional holders and their changes in shareholding.
Precision Trading with Irhythm Technologies Inc. (IRTC) Risk Zones
This article provides a detailed analysis of Irhythm Technologies Inc. (IRTC) with a focus on risk zones for precision trading. It highlights a potential negative sentiment shift, weak broader alignment, and an exceptional short setup with a 55.8:1 risk-reward ratio targeting a 16.0% downside. The report also outlines institutional trading strategies tailored for different risk profiles, including position, momentum breakout, and risk-hedging strategies, along with multi-timeframe signal analysis.
Precision Trading with Irhythm Technologies Inc. (IRTC) Risk Zones
This article provides a precision trading analysis for Irhythm Technologies Inc. (IRTC), highlighting a potential shift in positive near-term sentiment and a strong risk-reward short setup. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis.
IRTC|iRhythm Technologies Inc|Price:122.460|Chg%:+5.090
This article provides a detailed financial summary for iRhythm Technologies Inc. (IRTC), including its stock performance, market capitalization, and key financial indicators from its income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings and revenue figures, upcoming earnings, and an analyst rating of "STRONG BUY" as of July 29, 2026. The content also features FAQs providing insights into various financial metrics based on the FY2025 earnings report.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term iRhythm shareholders to contact them to discuss potential legal rights and options, including corporate governance reforms or financial relief. Shareholder involvement is emphasized as crucial for improving company policies and enhancing shareholder value.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) on behalf of investors who purchased securities before January 11, 2022, and still hold them. The investigation aims to determine if iRhythm and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist in the investigation.
Law firm investigates iRhythm officers over alleged stock price inflation via product misrepresentation
Kuehn Law, PLLC is investigating officers and directors of iRhythm Technologies for allegedly breaching fiduciary duties by misrepresenting their Zio AT monitor. The firm claims insiders falsely promoted the product's market potential, leading to artificially inflated stock prices. Investors who purchased shares before November 5, 2021, are encouraged to contact the law firm to protect their rights.
IRTC|iRhythm Technologies Inc|Price:112.260|Chg%:+3.060
This article provides a comprehensive stock analysis of iRhythm Technologies Inc (IRTC), highlighting its strong fundamentals, high growth potential, and fair valuation. The company's stock is rated a "Strong Buy" by multiple analysts with a target price of $178.00, indicating a significant upside. Key insights cover its healthy financial state, the high institutional ownership, and its sideways trading pattern, suggesting suitability for range-bound swing trading despite recent weak market performance.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, representing investors in securities fraud class actions.
iRhythm Technologies Inc (IRTC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for iRhythm Technologies Inc (IRTC). It notes that no dividends have been distributed by IRTC over the past five years. The page displays the current stock price, market cap, and links to various company and financial information.
iRhythm Technologies Inc (IRTC) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for iRhythm Technologies Inc (IRTC), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 14 analysts currently rate IRTC as a "Strong Buy" with an average price target of $220.00. The company's expected revenue for the next quarter is $219.32M, and its previous quarter's EPS was $0.17, outperforming the market expectation of -$0.43.
IRTC|iRhythm Technologies Inc|Price:109.436|Chg%:+1.766
iRhythm Technologies Inc. (IRTC) is a digital healthcare company specializing in solutions for detecting, predicting, and preventing cardiac disease through device-based technology. The company offers Zio System options for ambulatory cardiac monitoring and disclosed its key executives and their shareholdings. As of Q1 2026, institutional shareholding increased, and Commercial Payors accounted for the largest portion of its revenue.
Study Data Show Short-Term Holter Monitoring Misses AF Recurrence Post-Ablation in Pregnancy
New real-world study data from iRhythm Holdings Inc. indicate that short-term Holter monitoring often misses atrial fibrillation (AF) recurrence post-ablation and other arrhythmias in pregnant patients. The findings, presented at HRS 2026, suggest a shift towards continuous 14-day monitoring with devices like iRhythm's Zio ambulatory ECG is crucial for more accurate detection and better clinical decision-making. Extended monitoring revealed that a significant proportion of AF recurrences and clinically significant arrhythmias in pregnancy were detected beyond 48 hours, highlighting the limitations of current short-duration monitoring practices.
IRTC|iRhythm Technologies Inc|Price:108.010|Chg%:+0.340
This article provides an in-depth analysis of iRhythm Technologies Inc. (IRTC), highlighting its relatively healthy fundamentals, high growth potential, and "Strong Buy" analyst rating with a target price of $178.00. Despite recent stock market underperformance, the company's valuation is considered fair within its industry, and it shows strong revenue growth. The report also details the company's cardiac monitoring products and key financial indicators.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (IRTC) and its officers/directors. Investors who purchased iRhythm securities before January 11, 2022, and still hold them, are encouraged to participate in the investigation by visiting the firm's website or contacting them directly. The firm operates on a contingency fee basis, seeking reimbursement only if successful.
Technical Reactions to IRTC Trends in Macro Strategies
This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting near-term weak sentiment that may lead to a resumption of long-term weakness. It identifies a significant risk-reward short setup and offers three distinct AI-generated trading strategies with specific entry, target, and stop-loss parameters for different time horizons. The analysis suggests that resistance is being tested, and if it holds, support levels should be anticipated next.
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX)
This article highlights recent bullish analyst ratings for three healthcare companies: Irhythm Technologies (IRTC), Merck & Company (MRK), and Viking Therapeutics (VKTX). Analysts from BTIG, Scotiabank, and Canaccord Genuity reiterated Buy ratings, providing price targets and noting potential upsides based on current stock levels. The report emphasizes the positive sentiment within the Healthcare sector for these companies.
BTIG Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $185
BTIG has reiterated its Buy rating on iRhythm Technologies (IRTC.US) and maintained its target price of $185. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Needham Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $255
Needham has reiterated its Buy rating for iRhythm Technologies (IRTC.US) and maintained a target price of $255. This continuation of a positive outlook suggests the firm sees sustained value or growth potential in the company.
